QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
ESC Congress 2026 in Munich
Last week, our Senior Project Leader Kelsi Smith joined the global cardiology community at ESC Congress 2026 in Munich.
Four days of new evidence, clinical debate and evolving treatment approaches provided plenty to bring back to the Quantify team.
Some of Kelsi’s highlights included:
🔹Sessions on management of patients receiving direct oral anticoagulants (DOACs), including evolving evidence in atrial fibrillation of which with Kelsi […]
Pharmacoepidemiology in practice
This week, Kirk Geale, PhD and Jessica Young represented Quantify Research at the 42nd ISPE Annual Meeting in Milan.
Jessica joined the faculty for Intermediate Pharmacoepidemiology: Addressing Unmeasured Confounding through Study Design and Analysis.
Kirk contributed to Tomorrow’s Evidence 2.0: Replace, Refine, or Reframe the Evidence Pyramid? A Live Framework Build.
Different topics, but a common […]
New TLV guidance – What should pharma teams keep in mind for upcoming reimbursement submissions?
The TLV held a webinar on its new regulations, general advice and updated handbook, providing a timely opportunity to revisit several recent changes.
For those of us supporting reimbursement applications for new medicines in Sweden, several points are particularly worth keeping in mind:
🔹 Incidence and prevalence need greater visibility.
TLV is asking companies to report these for the full indication and, where relevant, for the proposed restricted population.
🔹 Productivity gains may […]
📢Publication alert!
We are pleased to share that the NORDSTAR manuscript ” From mild-to-moderate to severe asthma: Risk factors and patient profiles from the NORDSTAR cohort” has been published in the American Journal of Respiratory and Critical Care Medicine.
Using Danish nationwide registry data from the NORDSTAR collaboration platform, the study included 99,748 adults with mild-to-moderate asthma who experienced their first asthma exacerbation between 1 July 2000 and 31 December 2018.
Patients were […]
